Second-generation insulin analogs (glargine 300 U/mL and degludec) provide a more stable glucose profile and may have advantages over first-generation ones in reducing the incidence of NH in patients with T1D [29,30,31]. Here, INS is linked to type 1 diabetes mellitus.